Advertisement
Advertisement

LYRA

LYRA logo

Lyra Therapeutics, Inc. Common Stock

1.90
USD
Sponsored
+0.13
+7.06%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

1.85

-0.04
-2.11%

LYRA Earnings Reports

Positive Surprise Ratio

LYRA beat 11 of 23 last estimates.

48%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$190.74K
/
-$7.28
Implied change from Q3 25 (Revenue/ EPS)
+662.96%
/
+115.38%
Implied change from Q4 24 (Revenue/ EPS)
-8.74%
/
-9.00%

Lyra Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, LYRA reported earnings of -3.38 USD per share (EPS) for Q3 25, beating the estimate of -5.36 USD, resulting in a 36.94% surprise. Revenue reached 25.00 thousand, compared to an expected 198.90 thousand, with a -87.43% difference. The market reacted with a -1.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -7.28 USD, with revenue projected to reach 190.74 thousand USD, implying an increase of 115.38% EPS, and increase of 662.96% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Lyra Therapeutics, Inc. Common Stock reported EPS of -$3.38, beating estimates by 36.94%, and revenue of $25.00K, -87.43% below expectations.
The stock price moved down -1.55%, changed from $3.88 before the earnings release to $3.82 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 6 analysts, Lyra Therapeutics, Inc. Common Stock is expected to report EPS of -$7.28 and revenue of $190.74K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement